Harnessing peripheral DNA methylation differences in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease
Abstract
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease impacting an estimated 44 million adults worldwide. The causal pathology of AD (accumulation of amyloid-beta and tau), precedes hallmark symptoms of dementia by more than a decade, necessitating development of early diagnostic markers of disease onset, particularly for new drugs that aim to modify disease processes. To evaluate differentially methylated positions (DMPs) as novel blood-based biomarkers of AD, we used a subset of 653 individuals with peripheral blood (PB) samples in the Alzheimer’s disease Neuroimaging Initiative (ADNI) consortium. The selected cohort of AD, mild cognitive impairment (MCI), and age-matched healthy controls (CN) all had imaging, genetics, transcriptomics, cerebrospinal protein markers, and comprehensive clinical records, providing a rich resource of concurrent multi-omics and phenotypic information on a well-phenotyped subset of ADNI participants.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 15, 2020
- Source ID
- 10.1186/s13148-020-00864-y
Entities
People
- Andrew J. Saykin
- Aparna Vasanthakumar
- Bridget Riley-gillis
- Elizabeth Asque
- For The Alzheimer’s Disease Neuroimaging Initiative (adni)
- Gyan Srivastava
- Jeffrey F. Waring
- Justin W. Davis
- Karol Estrada
- Kelley Faber
- Kelly N. H. Nudelman
- Kenneth Idler
- Kwangsik Nho
- Liana G. Apostolova
- Qingqin S Li
- Shaun Grosskurth
- Sungeun Kim
- Tatiana Foroud
- Yu Sun
Organizations
- National Institutes of Health
- United States Department of Defense